Provider Resources
Education
HCP Consensus Statements from
CJON
HCP Toolkits
ctDNA Testing for Response Monitoring
BRAF Testing
Care Step Pathways
Side Effect Search
Videos
Decision Support Tools
Options for Stage II Melanoma
Options for Stage III Melanoma
Options for Stage IV Melanoma
Patient Resources
Patient Action Plans
Non-Invasive Evaluation Tools For Suspicious Spots
BRAF Q&A
ctDNA Testing Handout
Videos
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Provider Resources
Education
HCP Consensus Statements from
CJON
HCP Toolkits
ctDNA Testing for Response Monitoring
BRAF Testing
Care Step Pathways
Side Effect Search
Videos
Decision Support Tools
Options for Stage II Melanoma
Options for Stage III Melanoma
Options for Stage IV Melanoma
Patient Resources
Patient Action Plans
Non-Invasive Evaluation Tools For Suspicious Spots
BRAF Q&A
ctDNA Testing Handout
Videos
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Rhabdomyolysis Management
In the presence of pain, muscle weakness, vomiting, confusion, tea-colored urine, anticipate dose holds/discontinuations for immunotherapy
Provide intravenous fluids and corticosteroids; check creatine kinase levels
© 2024 The Melanoma Hub, Terranova Medica, LLC, and Integrita Foundation, LLC. All rights reserved.